Name: Can you speak to the efficacy of bimekizumab from the three pivotal head-to-head trials?
Uploaded: 2023-10-20T00:00:00.000Z
Description: Can you speak to the efficacy of bimekizumab from the three pivotal head-to-head trials?

Welcome to Dermbits! Watch short videos of KOLs answering your questions

thumbnail_dermbits-colorful.png

dermbits-colorful.png

Dermbits

UCB Bimz October 2023

Can you speak to the efficacy of bimekizumab from the three pivotal head-to-head trials?

Psoriasis

You. The efficacy of bimikizumab in the head to head trials showed statistically significant improvement compared to the other agents against which it was tested, which is not surprising. It blocks both IL 17 a and IL 17 f. We know that IL 17 a is the key cytokine in development of psoriasis, and we have other agents, notably secukinumab and ixicizumab, which block IL 17 a. I will point out that bridalumab, which blocks the receptor for all of the IL seventeen s, is also highly effective, but in the head to head trials that bibikizumab ran, it was superior, showed a statistically significant superior priority over the other biologics that are used for psoriasis.

Can you speak to the efficacy of bimekizumab from the three pivotal head-to-head trials?

Related CME